Screener / SEC EDGAR /CIK 0001865782 /10-K filed Feb 27, 2026, compared with Mar 6, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Home Health Care Services

BrightSpring Health Services, Inc. BTSG

Compare with peers Embed
SEC comment letters, last 20 years

1 review of BTSG's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Sep 22, 2023
Questions asked 48 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 4 UPLOAD
  2. 2. Questions in them 48 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-1

2023-09-22 to 2024-01-23 · 48 questions · 4 letters from the SEC, 5 from the company
No closing letter
Results discussion (MD&A)Risk factorsLegal and contingenciesSegmentsDebtNon-GAAP measuresAcquisitionsCybersecurityInventoryIncome taxesLiquidity and cash
SEC letter of Sep 22, 2023 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Draft Registration Statement on Form S-1 submitted August 28, 2023 · Cover Page
SEC asked (1)
We note your statement that you have applied to list your common stock on Nasdaq. Please state whether approval for listing on Nasdaq is a condition to closing of the offering. Once finalized, please ensure your disclosure is consistent with your underwriting agreement.
BTSG answered

No reply letter found.

Industry and Market Data, page ii
SEC asked (2)
We note your statement that "[w]hile we believe such information is reliable, we have not independently verified any third-party information. While we believe our internal company research, surveys, and estimates are reliable, such research, surveys, and estimates have not been verified by any independent source." It is not appropriate to directly or indirectly disclaim liability for statements in your registration
Rest of the question

statement. Please revise or specifically state that you take liability for these statements.

BTSG answered

No reply letter found.

Summary Highlights of Our Business, page 1
SEC asked (3)
We note your statement that you are "[a] leading, diversified, independent provider of home and community-based healthcare services in the United States." Please revise to provide support for your assertion that you are a leading provider and explain what independent provider means in this context.
BTSG answered

No reply letter found.

Summary Highlights of Our Business, page 1
SEC asked (4)
We note your statement here regarding your "over $1.75 trillion combined market opportunity," your statement on page 7 that "[t]he Senior and Specialty patients we serve represent a market opportunity of over $1.75 trillion" and similar statements on page 8 and throughout the prospectus.
Rest of the question

Please clarify how this $1.75 trillion figure is calculated and discuss any material assumptions underlying the estimate, including your assumed market penetration.

BTSG answered

No reply letter found.

Summary Highlights of Our Business, page 1
SEC asked (5)
We note your reference to "numerous businesses growing organically into the doubledigits." Please clarify what you mean by businesses in this context as it appears to be different than your two segments.
BTSG answered

No reply letter found.

Summary, page 1
SEC asked (6)
Your prospectus Summary should provide a balanced presentation of your business. Please revise to discuss the challenges you face, including, as examples only, competitive conditions in the markets you serve, regulatory risk as a result of your substantial reliance on government healthcare programs such as Medicare and Medicaid, and your level of indebtedness.
BTSG answered

No reply letter found.

Summary, page 1
SEC asked (7)
We note various statements in your prospectus regarding expectations or beliefs that do not appear to be attributed to the Company or an outside source. Please revise these statements to state that they are your beliefs or expectations or otherwise attribute the statements.
Rest of the question

For example, we note without limitation your statements: • on page 2: "The chronic conditions and long-term health needs of these patients not only represent an outsized share of health care spend today, but also are expected to drive a disproportionate share of future expenditures;" • on page 8: "Healthcare expenditures in the United States totaled $4.4 trillion in 2022 and are expected to reach $4.9 trillion in 2024;" • on page 12: "Over $40 billion in annual U.S. health care spending is attributed to hospital readmissions, and home health care can reduce 365-day post-discharge costs by more than $6,000 per patient;" • on page 19: "Seniors over the age of 65 are expected to grow at three percent a year by 2030, and the population size of people over age 85 is expected to double by 2040;" • on page 19: "There is an estimated six percent growth rate in the number of Seniors needing supportive care services, and 70% of adults over the age of 65 will need assistance at some point;" • on page 19: "Hospice services are projected to grow at seven to eight percent per year, and neuro rehab services are estimated to grow at eight percent per year;" and • on page 19: "Reimbursement rates for hospice services have increased by 2.0% on average per year since 2014, while home health spending in the U.S. is projected to increase by eight percent per year through at least 2028."

BTSG answered

No reply letter found.

Summary, page 1
SEC asked (8)
We note your reference to "excellent" and "world class" Net Promoter Scores. Here or elsewhere in the prospectus, please briefly explain what Net Promoter Scores are and how they are calculated. Please explain the criteria for "excellent" and "world class" ratings.
Rest of the question

Additionally, please explain why you have multiple different NPS ratings and if these reflect ratings at different times or for different aspects of your business.

BTSG answered

No reply letter found.

Summary, page 1
SEC asked (9)
We refer to your statement that you "provide home-based primary care, which is associated with a 50% reduction in hospitalization rate and a 20% reduction in emergency room visits." Please expand on this statement to explain what the baseline comparison is for these percentage reductions and what the association is between home-based primary care and these reductions.
Rest of the question

Additionally, please revise to attribute or otherwise explain the basis for these statements.

BTSG answered

No reply letter found.

Summary, page 1
SEC asked (10)
We note your statement that you "reduce the cost of long-term care for Behavioral patients by over $100,000 per year." Please revise to explain the baseline used for this comparison.
BTSG answered

No reply letter found.

Summary, page 1
SEC asked (11)
We refer to your statement that "These pharmacy services optimally manage medication regimens and drug utilization and minimize adverse medical effects, which reduce drug spending and help to capture potentially up to $2,400 in savings from increased medication adherence." Please explain how the $2,400 in potential savings is calculated, if it is a maximum potential benefit and the applicable timeframe for the
Rest of the question

savings (annual, lifetime, etc.).

BTSG answered

No reply letter found.

Summary, page 1
SEC asked (12)
We note your statement that you have "six-month line of sight on approximately 76% of our service volume and 69% line of sight on our service volume over a year." Please explain what line of sight means in this context.
BTSG answered

No reply letter found.

Summary, page 1
SEC asked (13)
Please provide data concerning your peers or your industry for all statements of comparison. For example, we note without limitation your statements: • on page 3: "We manage one of the nation’s largest independent platforms of both pharmacy and provider services offered on a daily basis in home and community settings;" • on page 3: "We are one of the largest independent providers of home and communitybased health
Rest of the question

services in the United States;" • on page 5: "We achieve hospitalization rates that are 30% lower than the national average in home-based primary care;" • on page 6: "As a result, and for example, our client and patient and associated family satisfaction scores are 99% for outpatient rehab services, 95% for home infusion patients, 81% per Home Health CAHPS, which is higher than the national average;" • on page 10: "Our best-in-class pharmacy support...;" • on page 11: "Our customer service and quality metrics are best-in-class as compared to peers, such as time-to-first-fill (4.2 day average turnaround time), 96.9% overall Medication Possession Ratio, or MPR, and 95% infusion patient satisfaction scores;" • on page 13: "we believe that our nurse-to-patient visit frequency and staffing ratio is well above industry averages;" • on pages 18-19: "While we have leading share and scale in a number of our patient services settings...;" and • on page 141: "we drive sales and marketing best practices across all geographies to drive referral and volume growth rates that are generally and consistently above market growth rates."

BTSG answered

No reply letter found.

Summary, page 1
SEC asked (14)
We note that you mention various ratings and scores. Please revise to further describe what these are and how they are calculated. For example, we note your statements: • on page 2: "We achieve 99% patient satisfaction in our outpatient rehab services, an 84% overall rating of care in hospice...;" • on page 5: "We achieve … an 84% overall rating of care in hospice, and four stars (out of five) in the Consumer
Rest of the question

Assessment of Healthcare Providers and Systems, or CAHPS, home health patient survey ratings;" patients, 81% per Home Health CAHPS, which is higher than the national average, 84% for Hospice CAHPS, and Seniors and Behavioral supportive care clients and families (or guardians) report an average satisfaction score of over 4 (out of 5);" to peers, such as … 96.9% overall Medication Possession Ratio, or MPR;" and • on page13: "We have an 8.8 Hospice Care Index, or HCI, score…"

BTSG answered

No reply letter found.

Our Value Proposition, page 5
SEC asked (15)
We note your statement that your "pace of acquisitions has been consistent, with 12, 12, and 6 deals completed each year in 2020, 2021, and 2022, respectively, and 2 deals completed in the six months ended June 30, 2023." Please remove or revise the reference to a consistent pace of acquisitions, as it appears the number of completed deals has declined.
BTSG answered

No reply letter found.

Pharmacy Solutions, page 10
SEC asked (16)
We note your statement that "[i]n 2020, 2021, and 2022, as a testament to our leading quality and service, we achieved “world-class” NPS scores of over 90, which also triggered quality incentive payments." Please explain what these incentive payments are, their general amount and by whom they were paid.
BTSG answered

No reply letter found.

Provider Services, page 12
SEC asked (17)
We note your statement here that the provider services you provide "consist of clinical and supportive care" and your statement on page 13 that "[y]our primary care clinicians optimize clinical and care decisions as they see and manage both Seniors and Behavioral (including I/DD) patients…" Please revise the description of your Provider Services segment to clarify if you directly employ physicians who are providing
Rest of the question

healthcare services to your patients or are otherwise practicing medicine. Please discuss applicable government regulations and laws concerning the corporate practice of medicine and feesplitting and how such regulations apply to your business model, including any associated risks and liabilities. Please also revise your Risk Factors and Business sections accordingly.

BTSG answered

No reply letter found.

Operational Excellence, page 15
SEC asked (18)
We refer to your statement that "[i]n 2022, the implementation of our PMOled continuous improvement program over the past seven years at the enterprise level has resulted in approximately $41.5 million of savings (in addition to annual efficiencies and savings work throughout field operations)." Please explain how the $41.5 million of savings is calculated, what baseline is being used for the comparison, and if this
Rest of the question

represents an annual figure for 2022 or cumulative savings over a seven-year period.

BTSG answered

No reply letter found.

Risk Factors · Risks Related to Our Business, page 32
SEC asked (19)
We note that on page 52 you state: "While we maintain liability coverage that we believe is appropriate given the nature and breadth of our operations, any claims against us in excess of insurance limits, or multiple claims requiring us to pay deductibles, as well as the potential impact on our brand or reputation as a result of being involved in any legal proceedings, could have a material adverse impact on our
Rest of the question

business, results of operations and financial condition" and on page 53 you state: "In addition, we self-insure for various risks, including employment class actions, False Claims Act actions, adverse regulatory actions, commercial contractual or commercial tort actions, and intellectual property actions." Please revise these risk factors to clarify, as you do elsewhere, that you are selfinsured for a substantial portion of your general and professional liability, automobile, workers’ compensation, and health benefit risk. Security breaches, loss of data, and other disruptions could compromise sensitive business or patient information..., page 50

BTSG answered

No reply letter found.

Risk Factors · Risks Related to Our Business, page 32
SEC asked (20)
We note your statement that "in March 2023, we experienced a ransomware attack that resulted in a breach of more than 6 million individuals’ personal information (including PHI); as a result of such incident, we notified the impacted individuals and applicable regulators and are currently subject to a HHS Office for Civil Rights investigation, various state regulatory investigations, and various lawsuits in
Rest of the question

connection with this incident." Please note whether you expect this ransomware attack and the associated investigations and lawsuits could have a material impact on your business. Additionally, we note that in general "you have been subject to HHS investigations with respect to data privacy and security incidents involving PHI in the past" and that your "systems and those of [y]our third-party service providers and business partners . . . have experienced, data or security breaches, cyberattacks (including ransomware), acts of vandalism, computer viruses, misplaced or lost data, human errors, or other similar events." Please revise as necessary to ensure all material investigations and events are described aside from the March 2023 example.

BTSG answered

No reply letter found.

Risks Related to Our Regulatory Framework · Many states have CON laws or other regulatory provisions..., page 59
SEC asked (21)
Please expand on this risk factor to discuss whether certificate of need laws or other similar regulatory provisions have materially impacted your business to date and if you expect them to have a material impact on your business going forward.
Rest of the question

For example, please note if you have applied for, and, if so, whether you have been granted or denied, a certificate of need in any of the states in which you currently operate or states into which you have attempted to expand. If material, please quantify the percentage of your business that relies upon certificates of need or other such state regulatory approvals.

BTSG answered

No reply letter found.

Risks Related to Our Indebtedness · Our variable rate indebtedness subjects us to interest rate risk..., page 67
SEC asked (22)
Please expand on this risk factor to discuss your interest rate swap agreements. In this regard, we note your statement on page 129 that as of June 30, 2023, your debt outstanding was $3.5 billion, of which $2.0 billion is fixed through interest rate swap agreements.
BTSG answered

No reply letter found.

Use of Proceeds, page 82
SEC asked (23)
Please revise the Use of Proceeds section to note that, pursuant to the terms of the Monitoring Agreement, you expect to pay a termination fee to the Managers in connection with the offering. Once known, please specify the expected amount of the termination fee.
BTSG answered

No reply letter found.

Management's Discussion and Analysis of Financial Condition and Results of Operations · Stable Reimbursement Environment Across our Portfolio of Businesses, page 96
SEC asked (24)
We note your statement that "[d]ue to the medical necessity of our services, which are lower cost than healthcare services provided in other settings and reduce ER, hospital and institutional facility utilization, we have a history of reimbursement stability characterized by low-to-mid single digit rate increases across our lines of business over the past 10 years." Please also note the average reimbursement rate
Rest of the question

increase over the previous 10 year period.

BTSG answered

No reply letter found.

Factors Affecting Results of Operations and Comparability, page 99
SEC asked (25)
We note your disclosure that on November 1, 2022 you completed the sale of Workforce Solutions for a base purchase price of $155.8 million, net of cash divested of $2.7 million. Please expand on this disclosure to note the use of proceeds from the sale.
BTSG answered

No reply letter found.

Impact of COVID-19 and CARES Act, page 100
SEC asked (26)
We note your statement that "[d]uring 2020 and 2021, we experienced an annual script reduction of approximately 2.7 million scripts when compared with our prepandemic levels in January and February 2020." Please also note the level of annual scripts during 2022 as compared to your pre-pandemic levels.
BTSG answered

No reply letter found.

Non-GAAP Financial Measures, page 114
SEC asked (27)
With reference to Question 100.01 Non-GAAP Financial Measures Compliance & Disclosure Interpretations, as updated December 13, 2022, please address the following comments related to certain of your adjustments made in the determination of Adjusted EBITDA: • We note that the startup costs, as more fully discussed in your response dated September 7, 2021, appear to be normal recurring cash operating expenses necessary
Rest of the question

to operate your business. It therefore appears that these costs should not be excluded from your non-GAAP performance measure. Please advise or revise to remove such adjustment; • We note that the management fees, as more fully discussed on page 197, appear to be normal recurring cash operating expenses necessary to operate your business. It therefore appears that these costs should not be excluded from your non-GAAP performance measure. Please advise or revise to remove such adjustment; • We note you have adjusted for significant project costs in each period since fiscal year 2020. We also note your response letter dated September 7, 2021 indicated that the project was not expected to recur within the next two years. Please more fully explain why you continue to incur costs for the migration of the Company’s financial general ledger system and related reporting systems to an updated platform. Fully explain the nature of these costs and how you concluded that they were not normal recurring cash operating expenses; and • We note that your legal costs and settlements, as disclosed in adjustment 5 and in your response dated September 7, 2021, represent potential settlement accruals and defense costs associated with certain PharMerica litigation matters associated with three historical cases. Please separately quantify the settlement accruals and defense costs. Please note that, notwithstanding the timing of these cases, your defense costs appear to be normal recurring cash operating expenses necessary to operate your business. It therefore appears that these costs should not be excluded from your non-GAAP performance measure. Please advise or revise to remove such adjustment.

BTSG answered

No reply letter found.

Business, page 130
SEC asked (28)
Please revise to describe interactions with regulators that led to measures being taken against the company or requiring material changes from the company as a result of noncompliance with applicable laws or regulations.
Rest of the question

This discussion should include, but not be limited to, the State of West Virginia, who we understand issued an Administrative Order in July of 2020 ordering an immediate admissions ban for all licensed, West Virginia locations and services of your subsidiary. Ensure appropriate risk factor disclosure is included as well. For example, we note some of these risks are disclosed on page 46, but there is no acknowledgment of prior issues.

BTSG answered

No reply letter found.

Our Value Proposition, page 133
SEC asked (29)
On page 134 you state: "Integrating our pharmacy and provider services to measure effectiveness across quality, costs, and patient experience provides potential opportunities to pursue additional per member per month, shared savings, and risk-taking (capitated) payment models and contracts, subsequent to current quality and shared savings based incentives in multiple payor and ACO contracts today." Please revise to
Rest of the question

explain capitated payment models, further explain your involvement with capitated payment contracts and disclose the risks associated with such models.

BTSG answered

No reply letter found.

Track Record of Strategic and Accretive M&A Across Our Platform with Proven Ability to · Execute, page 148
SEC asked (30)
Please balance this disclosure here concerning your successful M&A track record with disclosure concerning the debt incurred as part of these acquisitions. Legal Proceedings, page 167
BTSG answered

No reply letter found.

Track Record of Strategic and Accretive M&A Across Our Platform with Proven Ability to · Execute, page 148
SEC asked (31)
We note your description of a complaint filed in the United States District Court for the District of New Jersey against PharMerica on March 4, 2011. Please revise to note the relief sought in the case.
BTSG answered

No reply letter found.

Certain Relationships and Related Party Transactions, page 198
SEC asked (32)
Please revise to state the underwriting fees expected to be earned by KKR Capital Markets LLC from this offering.
BTSG answered

No reply letter found.

Certain Relationships and Related Party Transactions, page 198
SEC asked (33)
Page F-64 states that you have a Prime Vendor Agreement with AmerisourceBergen Drug Corporation, an affiliate of WBA, under which you purchase "a significant volume of inventory." Please tell us why this contract is not described here.
BTSG answered

No reply letter found.

Certain U.S. Federal Income Tax Consequences to Non-U.S. Holders, page 218
SEC asked (34)
We note the heading here and your statement that this section is a summary of "certain" U.S. federal income tax consequences. Please revise your disclosure here to clarify that this section addresses the material U.S. federal income tax considerations as opposed to “certain” material U.S. federal income tax considerations. Revise to provide similar changes to the disclosures starting on page A-56.
BTSG answered

No reply letter found.

General
SEC asked (35)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
BTSG answered

No reply letter found.

SEC letter of Oct 23, 2023 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Industry and Market Data, page iii
SEC asked (1)
We note your response to comment 4 and your disclosure that "statements in this prospectus regarding our $1.75 trillion combined market opportunity are based on the Centers for Medicare & Medicaid Services, or CMS, data, which projected Medicare expenditures to be $944 billion and Medicaid expenditures to be $805 billion in 2022" and "[t]he Company’s platform is purpose-built to address the full continuum of care
Rest of the question

and pharmacy services provided to patients in the United States today." Given that Medicare and Medicaid cover the full spectrum of healthcare services in the United States, please revise statements regarding your market opportunity to reflect the total addressable market for the two segments in which you operate or explain in more detail how your business model addresses the full continuum of healthcare services in the United States. For example, we note that Medicare Part A covers things such as inpatient hospital care and surgery which would appear to be a component of the projected $944 billion in expenditures but do not appear to be part of your business model. Finally, we also note your statement on page 2 of the prospectus that "[t]hese high-need and high-cost Senior and Specialty patients comprise a market of $1.75 trillion across our business." Please ensure that your estimated market opportunity is limited to the patient population you intend to serve. In this regard, we note that if the $1.75 trillion market opportunity represents the entirely of Medicare and Medicaid expenditures, the market opportunity could not be comprised solely of a subset of high-need and high-cost Senior and Specialty patients.

BTSG answered

No reply letter found.

Summary, page 1
SEC asked (2)
We note your response to previous comment 13, which we reissue in part. On page 11 you state: “Our customer service and quality metrics are best-in-class as compared to peers, such as time-to-first-fill (4.2 day average turnaround time), 96.9% overall Medication Possession Ratio, or MPR, and 95% infusion patient satisfaction scores." Please revise to provide these metrics for your peers that you are comparing
Rest of the question

yourself to. Who We Are, page 2

BTSG answered

No reply letter found.

Summary, page 1
SEC asked (3)
We note your revised disclosure in response to previous comment 14 and re-issue the comment in part. In addition to describing "MPR" and "NPS," please further describe how you calculate "patient satisfaction," "associated family satisfaction," "overall rating of care," and "Hospice Care Index, or HCI, score."
BTSG answered

No reply letter found.

Our Value Proposition, page 7
SEC asked (4)
We note your revised disclosure in response to previous comment 12 and re-issue the comment in part. Please explain what it means to have line of sight over service volume. If you are able to estimate future service volume based on the number of patients currently under care and the average lengths of stay from historical data, please explain what the remaining 24% or 31% of service volume outside the line of sight
Rest of the question

represents or why that portion of service volume cannot be estimated using the same calculation method.

BTSG answered

No reply letter found.

Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 115
SEC asked (5)
We note your response to prior comment 27. Notwithstanding your rationale for excluding start-up costs from your non-GAAP adjusted EBITDA measure, this adjustment appears to represent normal, recurring cash operating expenses and therefore inconsistent with the guidance in Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosure Interpretation. Please revise to remove the adjustment accordingly.
BTSG answered

No reply letter found.

Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 115
SEC asked (6)
Regarding your management fees, significant projects expenses, and legal costs excluded from your non-GAAP measure Adjusted EBITDA, please expand your disclosures to clearly explain why these costs are not normal, recurring operating expenses, similar to your response.
BTSG answered

No reply letter found.

Employees and Human Capital Resources, page 159
SEC asked (7)
We note that on page 159 you cite an approximately 80% retention of clinical positions in home health care, hospice care, and community and rehab care. Please revise to state the time period this statistic covers.
BTSG answered

No reply letter found.

Regulation · Corporate Practice of Medicine and Fee-Splitting Laws, page 165
SEC asked (8)
We note your revised disclosure in response to previous comment 17 and your statement that "[s]ome of the states in which we currently operate have laws that prohibit business entities, such as us, from practicing medicine, employing physicians to practice medicine..." Given that you directly employ physicians who provide healthcare services to your patients, please expand on this discussion to explain how you
Rest of the question

comply with state laws that prohibit you from employing physicians to practice medicine. Please note if you believe you are in compliance with such laws or if you do not engage in Provider Services in certain states.

BTSG answered

No reply letter found.

Licensing Laws and State Directives, page 165
SEC asked (9)
We note your revised disclosure in response to previous comment 28 and re-issue the comment in part. We note your statements on page 47 that "[i]n the past, regulators have taken measures against certain of our facilities and locations as a result of non-compliance with applicable laws and regulations." Please briefly describe the specific laws and regulations which led regulators to take measures against certain of
Rest of the question

your facilities and locations as well as the extent of your non-compliance with such requirements. To the extent material, please discuss any other specific incidents in addition to the July 2020 incident involving the West Virginia Department for Health and Human Resources. With respect to the July 2020 West Virginia incident, please expand on your disclosure to discuss the reason for the statewide admissions ban and explain how and when the ban orders were subsequently cleared. We note that you state the following on page 166: "For example, we self-reported an employee in West Virginia who failed to meet our standards of care, and we communicated with regulators as part of their investigation and as part of licensure surveys." Please revise to state the date of the self-reported issue and whether it was related to the admissions ban.

BTSG answered

No reply letter found.

Certain Relationships and Related Party Transactions · Transactions involving affiliates of Walgreen Stockholder, page 201
SEC asked (10)
Please revise to provide the termination provisions of the two agreements involving affiliates of Walgreen Stockholder.
BTSG answered

No reply letter found.

Preliminary, Unaudited Estimated Financial and Other Data as of and for the Year Ended · December 31, 2023, page 22
SEC asked (1)
We refer to your statements that "[o]ur actual results may be materially different from our estimates, which should not be regarded as a representation by us, our management or the underwriters as to our actual results as of and for the year ended December 31, 2023" and that investors "should not place undue reliance on these estimates." If you choose to disclose preliminary estimates, you should be able to assert
Rest of the question

that the actual results are not expected to differ materially from those reflected in the preliminary estimates. Further, it is not appropriate to directly or indirectly disclaim liability for statements in your registration statement. Accordingly, please delete these statements or revise to specifically state that you take liability for them.

BTSG answered
The Company has revised its disclosure on page 22 to remove these statements in their entirety.
Read in the reply
Legal Proceedings, page 175
SEC asked (2)
We note your disclosure that the estimated financial impact of the settlement of the Silver matter is $115.0 million, which you accrued in the nine months ended September 30, 2023. If known, please provide a general estimate of when you expect a final settlement agreement could be approved and cash payment of the settlement amount made.
Rest of the question

Please note the anticipated source of funds to be used to pay the settlement amount, including any anticipated increase in net debt and any related impacts such as a decrease in available borrowing capacity.

BTSG answered
The Company has revised its disclosure on page 175 in response to the Staff’s comment.
Read in the reply
Exhibits
SEC asked
We note that the legality opinions filed as Exhibits 5.1 and 5.2 assume that when the Board, or a duly authorized committee of the Board, has taken all necessary corporate action to authorize and approve the issuance of the respective securities, such securities will be validly issued, fully paid and nonassessable or will constitute valid and legally binding obligations of the Company enforceable against the Company
Rest of the question

in accordance with their terms. Once the Board has approved the 15.7027 for-one stock split of the Company’s common stock or taken any other requisite corporate action, please file revised opinions that do not assume appropriate corporate actions have been taken to authorize the issuance of the respective securities. For guidance, please see Section II.B.3.a of Staff Legal Bulletin No. 19 (CF).

BTSG answered
Pursuant to Rule 461 under the Securities Act of 1933, as amended, we attach the requests of our client, BrightSpring Health Services,

Inc., and of the underwriters that effectiveness of the above-referenced Registration Statement be accelerated to 4:00 p.m., Washington, D.C. time, on January 25, 2024, or as soon as practicable thereafter. We ask, however, that the

Securities and Exchange Commission staff not accelerate such effectiveness until we speak with you on that date.
Read in the reply

Also in this review: company letter, Jan 10, 2024, company letter, Jan 23, 2024, company letter, Jan 23, 2024

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 9 letters filed since 2023-09-25. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BTSG/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.